AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29655290 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 27
Study 29655290 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 27
Study 29141361 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 500 mg twice daily for day 0 to day 3 after PCI
Number of subjects: 641
Study 29141361 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional therapy only)
Number of subjects: 641
Study 25729164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip exercises
Number of subjects: 78
Study 25729164 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 78
Study 23607895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Treatment (CBT)
Number of subjects: 180
Study 23607895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Treatment supported by Information and Communication Technologies (CBT + ICT)
Number of subjects: 180
Study 23607895 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 180
Study 21310077 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 21310077 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose
Number of subjects: 0
Study 21310077 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (lisinopril, losartan, atorvastatin)
Number of subjects: 0
Study 19845453 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP (Transabdominal Preperitoneal hernia repair)
Number of subjects: 40
Study 19845453 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP (Totally Extraperitoneal hernia repair)
Number of subjects: 40
Study 19845453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TAPP and TEP procedures
Number of subjects: 40
Study 17098133 — intervention group
Group type: EXPERIMENTAL
Intervention: IVNC
Number of subjects: 26
Study 17098133 — intervention group
Group type: COMPARATOR
Intervention: DCMP
Number of subjects: 26
Study 15378097 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (moderate exercise programs)
Number of subjects: 0
Study 15378097 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (referrals to physical therapy and/or rehabilitation)
Number of subjects: 0
Study 15378097 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (encouraging physical activity)
Number of subjects: 0
Study 11331630 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (40 microg s.c. per day) initiated on cycle day 2 followed by exogenous gonadotrophins on cycle day 3
Number of subjects: 48
Study 11331630 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist (cetrorelix, 0.25 mg daily during late follicular phase)
Number of subjects: 48
Study 11331630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 9383647 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Behavior Check List (CBCL)
Number of subjects: 1964
Study 9383647 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Interview Schedule for Children (DISC)
Number of subjects: 1964
Study 8579131 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferating cell nuclear antigen (PCNA) immunohistochemical analysis
Number of subjects: 22
Study 3127846 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana containing 2.7% delta 9‐THC (M)
Number of subjects: 0
Study 3127846 — intervention group
Group type: COMPARATOR
Intervention: Marijuana containing 0.0% delta 9‐THC (P)
Number of subjects: 0
Study 3127846 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana containing 0.9% delta 9‐THC
Number of subjects: 0
Study 3127846 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana containing 1.4% delta 9‐THC
Number of subjects: 0
Study 30866853 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy children
Number of subjects: 883
Study 30866853 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ARIs
Number of subjects: 883
Study 30866853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococci non-susceptible to multiple beta-lactams
Number of subjects: 883
Study 30866853 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 19F
Number of subjects: 883
Study 30866853 — intervention group
Group type: EXPERIMENTAL
Intervention: Daycare attendance
Number of subjects: 883
Study 30866853 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccine serotypes
Number of subjects: 883
Study 28395984 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT) including neurodynamic techniques, functional massage, and carpal bone mobilization
Number of subjects: 140
Study 28395984 — intervention group
Group type: COMPARATOR
Intervention: Electrophysical Modalities (EM) including laser and ultrasound therapy
Number of subjects: 140
Study 26141535 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-controlled continuous cold flow device (Hilotherm® group)
Number of subjects: 47
Study 26141535 — intervention group
Group type: COMPARATOR
Intervention: Ice bag (control group)
Number of subjects: 47
Study 24103530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training (group 2)
Number of subjects: 172
Study 24103530 — intervention group
Group type: COMPARATOR
Intervention: Demonstration (group 1)
Number of subjects: 172
Study 17148774 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide administered concurrently
Number of subjects: 2123
Study 17148774 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide administered sequentially
Number of subjects: 2123
Study 17148774 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher p27 expression
Number of subjects: 2123
Study 17148774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin E expression
Number of subjects: 2123
Study 12962749 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy with polyclonal or monoclonal antilymphocytic antibodies associated with cyclosporine and prednisone (n=201)
Number of subjects: 379
Study 12962749 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine, mycophenolate mofetil, and prednisone (n=127)
Number of subjects: 379
Study 12962749 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus, mycophenolate mofetil, and prednisone (n=51)
Number of subjects: 379
Study 10078748 — intervention group
Group type: EXPERIMENTAL
Intervention: pimozide (n = 6)
Number of subjects: 10
Study 10078748 — intervention group
Group type: COMPARATOR
Intervention: withdrawn from therapy (n = 4)
Number of subjects: 10
Study 7732997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes treatment
Number of subjects: 1441
Study 7732997 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes treatment
Number of subjects: 1441
Study 1682228 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg
Number of subjects: 165
Study 1682228 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg + Amiloride 5 mg
Number of subjects: 165
Study 1682228 — intervention group
Group type: COMPARATOR
Intervention: Diuretic group
Number of subjects: 165
Study 1682228 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril group
Number of subjects: 165
Study 7124828 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice
Number of subjects: 24
Study 7124828 — intervention group
Group type: COMPARATOR
Intervention: Constant practice
Number of subjects: 24
Study 7124828 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 24
Study 31270896 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 80
Study 31270896 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation training
Number of subjects: 80
Study 31270896 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 31270896 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity recommendation from the World Health Organization
Number of subjects: 80
Study 30246560 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic stress group (reading a news article about uncertain financial future)
Number of subjects: 178
Study 30246560 — intervention group
Group type: COMPARATOR
Intervention: Control group (reading a news article about a tour of the Royal Canadian Mint)
Number of subjects: 178
Study 30246560 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic stress group
Number of subjects: 178
Study 26984523 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook (n = 14)
Number of subjects: 41
Study 26984523 — intervention group
Group type: COMPARATOR
Intervention: Online diary website (active control, n = 13)
Number of subjects: 41
Study 26984523 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (n = 14)
Number of subjects: 41
Study 25744453 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs) with organoleptic masking (L-menthol, aspartame, thaumatin, cinnamon) and physical masking
Number of subjects: 10
Study 25744453 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs) with physical masking
Number of subjects: 10
Study 25744453 — intervention group
Group type: COMPARATOR
Intervention: Orally disintegrating tablets (ODTs) without organoleptic masking
Number of subjects: 10
Study 22999568 — intervention group
Group type: COMPARATOR
Intervention: Metronome-paced walking
Number of subjects: 25
Study 22999568 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced brisk walking
Number of subjects: 25
Study 22999568 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking at 2.7 mph
Number of subjects: 25
Study 22999568 — intervention group
Group type: COMPARATOR
Intervention: Metronome-guided moderate pace walking
Number of subjects: 25
Study 21192769 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 325
Study 21192769 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 325
Study 18678570 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized vestibular rehabilitation for 12 weeks
Number of subjects: 53
Study 18678570 — intervention group
Group type: COMPARATOR
Intervention: General instructions
Number of subjects: 53
Study 16176314 — intervention group
Group type: EXPERIMENTAL
Intervention: Small caliber audio-Doppler probe (AU group, n = 42)
Number of subjects: 81
Study 16176314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scanner (US group, n = 39)
Number of subjects: 81
Study 16176314 — intervention group
Group type: COMPARATOR
Intervention: Both methods (audio-Doppler and ultrasound scanner)
Number of subjects: 81
Study 12948713 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 12948713 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 12948713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10841922 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceroltrinitrate (GTN; 0.4 mg/h)
Number of subjects: 0
Study 10841922 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceroltrinitrate (GTN; 0.4 mg/h) + Vitamin C (Vit-C; 55 μg/kg/min)
Number of subjects: 0
Study 10841922 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (Vit-C; 55 μg/kg/min) alone
Number of subjects: 0
Study 8905031 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional doses of L-asparaginase (L-ASE) 10,000 IU/sqm every three days during the induction phase (8 doses, first exposure)
Number of subjects: 54
Study 8905031 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional or high doses of L-asparaginase (L-ASE) during the second or third exposures (high-dose L-ASE 25,000 IU/sqm weekly for a total of 20 doses)
Number of subjects: 54
Study 2065789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 285
Study 2065789 — intervention group
Group type: COMPARATOR
Intervention: LH-timed intercourse
Number of subjects: 285
Study 2065789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) for severe semen defect
Number of subjects: 285
Study 2065789 — intervention group
Group type: EXPERIMENTAL
Intervention: First IUI cycle
Number of subjects: 285
Study 2065789 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall IUI pregnancies
Number of subjects: 285
Study 6125161 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 3
Study 6125161 — intervention group
Group type: EXPERIMENTAL
Intervention: Org NC 45
Number of subjects: 3
Study 6125161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 3
Study 31411039 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy (defined by three items from Geriatric Depression Scale)
Number of subjects: 1679
Study 30554923 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT, n = 6)
Number of subjects: 17
Study 30554923 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MOD, n = 5)
Number of subjects: 17
Study 30554923 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (CON, n = 6)
Number of subjects: 17
Study 28911991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with concomitant prophylactic sclerostomy (sclerostomy group, n = 29)
Number of subjects: 60
Study 28911991 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery alone (control group, n = 31)
Number of subjects: 60
Study 27401184 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 667
Study 25188655 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based training (rD)
Number of subjects: 50
Study 25188655 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient training (rH)
Number of subjects: 50
Study 22805300 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g fibrinogen concentrate
Number of subjects: 245
Study 22805300 — intervention group
Group type: COMPARATOR
Intervention: 100 ml isotonic saline (placebo)
Number of subjects: 245
Study 19250300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser (NAFL) 1,550 nm
Number of subjects: 12
Study 19250300 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL) 595 nm
Number of subjects: 12
Study 16960847 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded pairs comparison method for assessing preferences for specialized nurse home visits for pain management
Number of subjects: 0
Study 16960847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordered-response regression models using graded pairs data
Number of subjects: 0
Study 14999613 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir, lamivudine, and zidovudine
Number of subjects: 10
Study 12051112 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (Menorest, 50 micrograms)
Number of subjects: 25
Study 12051112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9797622 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 88
Study 9797622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine
Number of subjects: 88
Study 9797622 — intervention group
Group type: COMPARATOR
Intervention: Both morphine and diamorphine
Number of subjects: 88
Study 7618661 — intervention group
Group type: EXPERIMENTAL
Intervention: 51W89 besylate 0.1 mg.kg‐1
Number of subjects: 19
Study 7618661 — intervention group
Group type: EXPERIMENTAL
Intervention: 51W89 besylate 0.15 mg.kg‐1
Number of subjects: 19
Study 7618661 — intervention group
Group type: EXPERIMENTAL
Intervention: 51W89 besylate 0.2 mg.kg‐1
Number of subjects: 19
Study 7618661 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.5 mg.kg‐1
Number of subjects: 19
Study 7618661 — intervention group
Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 19
Study 2372674 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight catheter removal
Number of subjects: 0
Study 2372674 — intervention group
Group type: COMPARATOR
Intervention: Early morning catheter removal
Number of subjects: 0
Study 368703 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprothixene 50 mg b.d. (twice daily) to outpatients
Number of subjects: 0
Study 368703 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprothixene 50 mg every 6 hours to inpatients for 5 days
Number of subjects: 0
Study 31234864 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Interpersonal Therapy (MIT)
Number of subjects: 80
Study 31234864 — intervention group
Group type: COMPARATOR
Intervention: Structured Clinical Management (SCM)
Number of subjects: 80
Study 28891826 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.375% ropivacaine
Number of subjects: 0
Study 28891826 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of 0.375% ropivacaine
Number of subjects: 0
Study 25590323 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone stent
Number of subjects: 91
Study 25590323 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene (polypropylene) stent
Number of subjects: 91
Study 25590323 — intervention group
Group type: EXPERIMENTAL
Intervention: Otologic T‐tube stent
Number of subjects: 91
Study 25590323 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 91
Study 25590323 — intervention group
Group type: COMPARATOR
Intervention: Comparison between silicone and Prolene
Number of subjects: 91
Study 24818429 — intervention group
Group type: EXPERIMENTAL
Intervention: On the Way Home (OTWH) aftercare program
Number of subjects: 82
Study 24818429 — intervention group
Group type: COMPARATOR
Intervention: Traditional aftercare supports
Number of subjects: 82
Study 21806387 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 LOF alleles (specifically two LOF alleles)
Number of subjects: 189
Study 21806387 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotypes (gene-dose effect)
Number of subjects: 189
Study 21806387 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 LOF allele presence
Number of subjects: 189
Study 21806387 — intervention group
Group type: COMPARATOR
Intervention: PON-1 and ABCB1 genotypes
Number of subjects: 189
Study 19181226 — intervention group
Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release
Number of subjects: 128
Study 19181226 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-portal endoscopic carpal tunnel release
Number of subjects: 128
Study 17098626 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal (aluminium-free, virosome-adjuvanted vaccine)
Number of subjects: 529
Study 17098626 — intervention group
Group type: COMPARATOR
Intervention: Havrix (aluminium-adsorbed HAV vaccine)
Number of subjects: 529
Study 17098626 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal
Number of subjects: 529
Study 17098626 — intervention group
Group type: COMPARATOR
Intervention: Havrix
Number of subjects: 529
Study 15517641 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (80 mg triamcinolone acetonide)
Number of subjects: 80
Study 15517641 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic (1% mepivacaine)
Number of subjects: 80
Study 11273918 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS guided (BIS)
Number of subjects: 202
Study 11273918 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 202
Study 9332238 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 1-antitrypsin augmentation therapy
Number of subjects: 22
Study 9332238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8466026 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (n = 14)
Number of subjects: 31
Study 8466026 — intervention group
Group type: COMPARATOR
Intervention: Isotonic crystalloid (n = 14)
Number of subjects: 31
Study 8466026 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 31
Study 2879477 — intervention group
Group type: EXPERIMENTAL
Intervention: tertatolol 5 mg
Number of subjects: 32
Study 2879477 — intervention group
Group type: COMPARATOR
Intervention: acebutolol 400 mg
Number of subjects: 32
Study 29331635 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg sotatercept
Number of subjects: 74
Study 29331635 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg sotatercept
Number of subjects: 74
Study 29331635 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg sotatercept
Number of subjects: 74
Study 29331635 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg sotatercept
Number of subjects: 74
Study 29331635 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg sotatercept
Number of subjects: 74
Study 29331635 — intervention group
Group type: EXPERIMENTAL
Intervention: High transfusion burden
Number of subjects: 74
Study 29331635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low transfusion burden
Number of subjects: 74
Study 29331635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept (all doses)
Number of subjects: 74
Study 27636206 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW carbohydrate solution (1.2 g•kg•bw‐1 of 10%)
Number of subjects: 16
Study 27636206 — intervention group
Group type: EXPERIMENTAL
Intervention: LMW carbohydrate solution (1.2 g•kg•bw‐1 of 10%)
Number of subjects: 16
Study 27636206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 27636206 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW vs LMW carbohydrate solutions
Number of subjects: 16
Study 27636206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HMW and LMW carbohydrate solutions
Number of subjects: 16
Study 24431912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate length adult-colonoscope
Number of subjects: 507
Study 24431912 — intervention group
Group type: COMPARATOR
Intervention: Long length adult-colonoscope
Number of subjects: 507
Study 22335889 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy (solution-focused or psychodynamic therapy, combined)
Number of subjects: 326
Study 22335889 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychotherapy (psychodynamic)
Number of subjects: 326
Study 22335889 — intervention group
Group type: COMPARATOR
Intervention: Short-term therapy
Number of subjects: 326
Study 20594096 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based, stage‐tailored folic acid intervention
Number of subjects: 408